News

EyePoint Pharmaceuticals Enhances Talent with Stock Options Grant

EyePoint Pharmaceuticals Enhances Talent with Stock Options Grant

EyePoint Pharmaceuticals Announces New Stock Option Grants

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), based in Watertown, Massachusetts, has recently made a significant move to enhance its team by granting non-statutory stock options to new employees. This initiative occurs outside the parameters of the Company’s current Long-Term Incentive Plan, adhering to the NASDAQ Listing Rule 5635(c)(4). The goal of this strategy is to attract talented individuals who can contribute to the advancement of therapies aimed at improving the lives of patients afflicted with severe retinal diseases.

Details of the Stock Options Grant

The Company has generously awarded stock options allowing the purchase of up to 65,000 shares ofEyePoint common stock shared among four new hires. These grants were formalized on April 15, 2025, following endorsements from the Compensation Committee. The exercise price is set at $5.67 per share, reflecting the previous day’s closing price, and these options will remain valid for up to ten years.

Vesting for these options is structured over four years, commencing with a 25% allocation vesting one year after the grant date. The remaining 75% will vest monthly over the ensuing three years. This phased approach to vesting emphasizes the importance of continued service, aiming to reinforce long-term commitment to EyePoint's mission.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a forward-thinking biopharmaceutical company focused on the research and development of innovative treatments for serious retinal diseases. Utilizing its proprietary Durasert E™ technology, the Company is pioneering advanced methods for sustained intraocular drug delivery. The star of their pipeline is DURAVYU™, a novel investigational treatment designed for VEGF-mediated retinal diseases. This medicine combines vorolanib, a selective tyrosine kinase inhibitor, with the Durasert E™ platform.

DURAVYU is currently undergoing critical Phase 3 trials for wet age-related macular degeneration (wet AMD) and has recently completed a Phase 2 study aimed at diabetic macular edema (DME). With encouraging preliminary results from the VERONA clinical trial, EyePoint plans to engage with regulatory agencies in the near future to discuss pivotal trials.

Innovative Treatments in Development

The Company’s diverse pipeline also features EYP-2301, a TIE-2 agonist designed to work in conjunction with the proven Durasert E™ technology. This formulation aims to potentially enhance treatment outcomes for patients with severe ocular conditions. Excitingly, the Durasert drug delivery technology has already been effectively used in four FDA-approved treatments, which have benefited thousands of patients across various conditions.

EyePoint collaborates with Equinox Sciences, a Betta Pharmaceuticals affiliate, which exclusively licenses vorolanib for treating all eye diseases outside certain Asian markets. This partnership strengthens EyePoint’s position as an innovator in targeted ophthalmic therapies.

Future Directions and Impact

As EyePoint Pharmaceuticals paves the way for groundbreaking treatments, it focuses on merging advanced technology with clinical research to deliver solutions that improve patient care. The ongoing commitment to innovation and attracting skilled professionals through initiatives like the recent stock options grant reflects the Company’s dedication to overcoming challenges in retinal disease management.

With a keen eye towards the future, EyePoint is poised to become a leader in the biopharmaceutical sector, combining its innovative spirit with effective treatments to provide hope to patients battling serious retinal conditions.

Frequently Asked Questions

What are the recent stock option grants by EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals has granted non-statutory stock options totaling 65,000 shares to four new employees as an incentive.

Why are these stock options significant?

These grants aim to attract and retain top talent essential for furthering EyePoint's mission in developing innovative retinal disease therapies.

What is the exercise price of the stock options?

The exercise price for the stock options is set at $5.67 per share, based on the closing price on the day of the grant.

What is DURAVYU™ and why is it important?

DURAVYU™ is EyePoint’s investigational treatment for retinal diseases, currently in Phase 3 trials, expected to help improve outcomes for patients with wet AMD.

How does EyePoint Pharmaceuticals contribute to retinal disease treatment?

EyePoint focuses on innovative drug delivery methods and has multiple therapies in development designed to enhance the quality of care for patients with severe retinal diseases.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain

Updated Category News Views 50

A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 58

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 0

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 39

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 116

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 55

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 13

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 65

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading

Top 5 Most Recently Viewed Articles

BlackBerry QNX and Pi Square Join Forces to Advance Indian Tech

Updated Category News Views 333

BlackBerry QNX Partners with Pi Square Technologies BlackBerry Limited (NYSE: BB) is experiencing a notable increase in share prices, reflecting growing investor confidence. Expanding Horizons for Engineers Recently, BlackBerry’s QNX division announced an exciting multi-year collaboration with Pi Square Technologies. This initiative aims to train thousands of engineers...

Continue Reading
Investors Urged to Act: Investigating DexCom Securities Claims

Updated Category News Views 67

Understanding the Ongoing Investigations into DexCom Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims on behalf of investors affected by losses in DexCom, Inc. (NASDAQ: DXCM). This inquiry is a direct response to significant concerns raised about the company's business practices and market performance. The Scope...

Continue Reading
Legal Battle Heats Up for Michigan Auto Attorney Over CURE

Updated Category News Views 299

Michigan Attorney Faces Legal Challenges Amid CURE Controversy In a recent turn of events, an attorney from Michigan is experiencing the challenges of navigating legal waters after speaking out against CURE Auto Insurance. The attorney, Steven M. Gursten, along with his firm Michigan Auto Law, is embroiled in lawsuits that highlight serious concerns about consumer...

Continue Reading
Investors of Joint Stock Company Kaspi.kz (KSPI) Take Action Now

Updated Category News Views 120

Investors of Joint Stock Company Kaspi.kz (NASDAQ: KSPI) Take Action Attention investors of Joint Stock Company Kaspi.kz, also known as KSPI! A recent report has raised serious concerns regarding the company's activities, prompting investors who have experienced losses to consider their options in filing a securities fraud lawsuit. These troubling developments are crucial...

Continue Reading
Investors Guide: Urgent Action Needed for Western Asset Fund

Updated Category News Views 130

Introduction to the Class Action The Rosen Law Firm, a prominent name in investor rights advocacy, is urging investors in the Western Asset Management Company mutual funds to take action before an important deadline. If you invested in the 'Western Asset US Core Bond Fund' or the 'Western Asset Core Plus Bond Fund' during the designated class period, this message is...

Continue Reading